Bausch Health (TSX:BHC) ROCE %: -18.02% (As of Mar. 2026)


TSX:BHC Bausch Health Companies Inc TSX:BHC
64 GF Score
Price C$7.10
GF Value C$11.06
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Bausch Health ROCE %?

Bausch Health TSX:BHC +4.11% 64 ROCE % is -18.02% as of Mar. 2026. GuruFocus rates TSX:BHC with a GF Score™ of 64/100 and a GF Value™ of C$11.06 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bausch Health's annualized ROCE % for the quarter that ended in Mar. 2026 was -18.02%.

Bausch Health  (TSX:BHC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bausch Health ROCE % Related Terms

Bausch Health ROCE % Historical Data

* Premium members only.

The historical data trend for Bausch Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health ROCE % Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 6.02 4.16 7.50 9.25

Bausch Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.42 10.62 11.44 8.18 -18.02
TSX:BHC
64GF Score
Bausch Health Companies Inc TSX:BHC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch Health ROCE % Calculation

Bausch Health's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=2718.995/( ( (37787.318 - 9619.574) + (36371.897 - 5766.31) )/ 2 )
=2718.995/( (28167.744+30605.587)/ 2 )
=2718.995/29386.6655
=9.25 %

Bausch Health's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-5224.576/( ( (36371.897 - 5766.31) + (33611.256 - 6215.16) )/ 2 )
=-5224.576/( ( 30605.587 + 27396.096 )/ 2 )
=-5224.576/29000.8415
=-18.02 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -18.02% mean?
Bausch Health (TSX:BHC) has a ROCE % of -18.02% as of Mar. 2026.
Is Bausch Health's ROCE % too high?
Bausch Health's current ROCE % is -18.02%. Overall, Bausch Health has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's ROCE % compare to ZTS?
Bausch Health's ROCE % of -18.02% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current ROCE % is -18.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (TSX:BHC) is currently considered Possible Value Trap. The stock's GF Value™ is C$11.06, compared to a current price of C$7.10 — trading 35.8% below its estimated fair value. The current ROCE % is -18.02%. Bausch Health's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Bausch Health (TSX:BHC), the current ROCE % is -18.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (TSX:BHC) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of C$7.10 is trading 35.8% below its estimated GF Value™ of C$11.06. GuruFocus considers Bausch Health to be Possible Value Trap.

Key valuation signals for TSX:BHC:

  • ROCE %: -18.02%
  • GF Value™: C$11.06 vs. price of C$7.10 (35.8% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TSX:BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
64GF Score

Get the complete analysis for TSX:BHC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$7.10
Price
C$11.06
GF Value